Clifford A. Hudis, MD: A Message From ASCO’s CEO
2024 ASCO Annual Meeting
Clifford A. Hudis, MD, of the American Society of Clinical Oncology (ASCO), talks about the 2024 Annual Meeting, and a focus on the compassionate side of cancer care.
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Welcome, everybody, to the 60th Annual ASCO Meeting. This meeting is an especially meaningful and exciting one for me because this comes on the heels of decades of really powerful advances across all of oncology, including, of course, targeted therapy, small molecules, immunotherapy, and engineered cells, among many other advances that I'd say in the last five to 10 years have truly transformed oncology. But what makes this year's meetings especially exciting, is that we have coupled this with a call for humanism in medicine and a reminder of the privilege of caring for patients and families through this most difficult time. Our president, Dr. Lynn Schuchter, who's been on the leading edge of the most exciting advances in cancer, especially those in melanoma, at the same time is one of the most compassionate, holistic kinds of physicians anyone could hope to see, and she brings that with passion to this meeting. So we're very, very excited by the inclusion of so many new resources and learnings for our community to help them help their patients around the world more effectively than ever before.
The ASCO Post Staff
Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Susan Halabi, PhD, of the Duke Cancer Institute and Duke University School of Medicine, discuss a clinical-genetic model that identified novel circulating tumor DNA alterations that are prognostic of overall survival and may help to classify patients with metastatic castration-resistant prostate cancer into risk groups useful for selecting trial participants (Abstract 5007).
The ASCO Post Staff
Emily L. Podany, MD, of Washington University, St. Louis, discusses disparities in the use of PI3K inhibitors for Black patients with estrogen receptor–positive, HER2-negative metastatic breast cancer while other drugs that do not require genomic profiling were similarly used (Abstract 1017).
The ASCO Post Staff
Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham, discusses recent findings from the CARTITUDE-4 trial showing that, in patients with lenalidomide-refractory functional high-risk multiple myeloma after one prior line of treatment, ciltacabtagene autoleucel improved outcomes vs the standard of care (Abstract 7504).
The ASCO Post Staff
Belinda Lee, MBBS, of Peter MacCallum Cancer Centre, Northern Health, Walter & Eliza Hall Institute, Melbourne, discusses findings from the AGITG DYNAMIC-Pancreas trial on the potential role of serial circulating tumor DNA testing after upfront surgery to guide adjuvant chemotherapy for early-stage disease (Abstract 107).
The ASCO Post Staff
Sherene Loi, MD, PhD, of Peter MacCallum Cancer Centre, discusses a circulating tumor DNA (ctDNA) analysis from a cohort of patients with early-stage breast cancer who were enrolled in the monarchE trial. This large cohort was studied to look at the usefulness of a personalized tumor-informed assay for ctDNA detection in early stage high-risk patients (LBA507).
